Crf2 receptor agonists and their use in therapy
US-2025243255-A1 · Jul 31, 2025 · US
This page is not indexed by search engines while we improve data quality.
Evers Andreas patents
Evers Andreas is listed as an inventor on 65 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Evers Andreas |
| Total patents | 65 |
| First publication | Apr 23, 2015 |
| Latest publication | Jul 31, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US-2024366727-A1 · Nov 7, 2024 · US
New Peptides as Potent and Selective GIP Receptor Agonists
US-2024360194-A1 · Oct 31, 2024 · US
Vhh-based nkp30 binders
US-2024287177-A1 · Aug 29, 2024 · US
Glp-1r agonist / fgf21 fusion proteins
US-2023265152-A1 · Aug 24, 2023 · US
Glp-1r agonistic peptides with reduced activity
US-2023250147-A1 · Aug 10, 2023 · US
Peptides as selective gip receptor agonists
US-2023103631-A1 · Apr 6, 2023 · US
Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US-2022401523-A1 · Dec 22, 2022 · US
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
US-11141489-B2 · Oct 12, 2021 · US
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
US-10806797-B2 · Oct 20, 2020 · US
Recent patents
Latest publications not already listed above.
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
US-10792367-B2 · Oct 6, 2020 · US
Exendin-4 derivatives as dual GLP1/glucagon agonists
US-10758592-B2 · Sep 1, 2020 · US
Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US-2020261542-A1 · Aug 20, 2020 · US
Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
US-2020262885-A1 · Aug 20, 2020 · US
Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
US-2020155688-A1 · May 21, 2020 · US
FGF21 compound / GLP-1R agonist combinations with optimized activity ratio
US-10583174-B2 · Mar 10, 2020 · US
Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
US-10538567-B2 · Jan 21, 2020 · US
Compounds as peptidic GLP1/glucagon/GIP receptor agonists
US-10519211-B2 · Dec 31, 2019 · US
Functionalized Exendin-4 derivatives
US-10253079-B2 · Apr 9, 2019 · US
Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate
US-2018289822-A1 · Oct 11, 2018 · US
Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US-2018236037-A1 · Aug 23, 2018 · US
Exendin-4 derivatives as dual glp1/glucagon agonists
US-2018185450-A1 · Jul 5, 2018 · US
Compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
US-2018155406-A1 · Jun 7, 2018 · US
Compounds as peptidic glp1/glucagon/gip receptor agonists
US-2018155407-A1 · Jun 7, 2018 · US
Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
US-2018154005-A1 · Jun 7, 2018 · US
Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US-9982029-B2 · May 29, 2018 · US
Exendin-4 derivatives as selective glucagon receptor agonists
US-9932381-B2 · Apr 3, 2018 · US
Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
US-9834527-B2 · Dec 5, 2017 · US
Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US-9789165-B2 · Oct 17, 2017 · US
Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US-9775904-B2 · Oct 3, 2017 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Sanofi Sa | 64 |
| Merck Patent Gmbh | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P3/10 | 57 |
| A61P3/04 | 46 |
| C07K14/605 | 45 |
| A61K38/26 | 41 |
| A61K45/06 | 36 |